Medicare Payment Demo Would Put Often-Prescribed Cancer Drugs ‘Underwater’
Executive Summary
Community oncology practices and hospitals strongly object to CMS’ plan for testing different reimbursement formula Part B drugs, which is expected to particularly impact treatments for cancer, arthritis and eye disease.
You may also be interested in...
CMS Cancels Part B Demo Before HHS Secretary-Designate Price Does
President-elect Trump’s selection for HHS secretary, Rep. Tom Price, R-Ga., has been an outspoken critic of the proposed Medicare Part B drug demonstration project.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.